Nonalcoholic Steatohepatitis | Disease Landscape & Forecast | G7 | 2023
The market for nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease (NAFLD), has great untapped potential owing to the lack of approved treatment options and the disease’s high prevalence. The body of evidence for the significant burden the disease places on healthcare systems is accumulating, particularly with respect to the increased risk of cardiovascular disease, liver failure, and liver transplantation. The lack of treatment options and limited awareness of NASH and its complications have kept diagnosis and treatment rates low. Despite guidelines recommending certain off-label medications, prescribing is usually limited to specialists caring for patients with more-advanced disease. However, with more education about the disease, development of novel diagnostic tools, and approved medical therapies becoming available, diagnosis and treatment rates will increase and drive growth of the overall market. Over the 2022-2032 forecast period, the NASH market will see launches of the first agents from a rich pipeline of emerging therapies, which will fuel massive market expansion.
Questions answered:
- What is the prevalence of NASH, and what is driving the growth of this indication?
- How is NASH being managed? With no approved medications, how are physicians using available prescription medications off-label to treat the disease?
- Which emerging therapy will garner the greatest share in the nascent branded therapy market?
- Where will Madrigal’s resmetirom, Novo Nordisk’s semaglutide, and Akero Therapeutics’ efruxifermin fit in the evolving NASH treatment paradigm?
CONTENT HIGHLIGHTS
- Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
- Primary research: 25 country-specific interviews with thought-leading gastroenterologists and hepatologists. Supported by survey data collected for this and other Clarivate research.
- Epidemiology: Diagnosed prevalence of NASH by country; population segmentation by stage of fibrosis.
- Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
- Market forecast features: 10-year, annualized, drug-level sales and patient share of key NASH therapies through 2032, segmented by brands and epidemiological subpopulations.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
